What question did this study set out to answer?

To evaluate the safety and effectiveness of switching stable schizophrenia patients to xanomeline-trospium combination therapy.

April 10, 2026

Trial shows safety of switch to xanomeline‐trospium combination in stable patients

Key Points

To evaluate the safety and effectiveness of switching stable schizophrenia patients to xanomeline-trospium combination therapy.
Conducted a 52-week open-label trial
Participants were psychiatrically stable adults with schizophrenia
Switched from prior antipsychotics to xanomeline and trospium chloride
No new safety issues were identified during the trial
Improvements observed in schizophrenia symptom severity measures

Abstract

Psychiatrically stable adults with schizophrenia were safely switched from their prior antipsychotic to the combination of xanomeline and trospium chloride, with no new safety issues uncovered, a 52‐week open‐label trial has found. The drug combination also led to improvements on measures of schizophrenia symptom severity. Results of the study were published online Jan. 7, 2026, in Schizophrenia Research .

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Journals

The Brown University Psychopharmacology Update

Actions

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Trial shows safety of switch to xanomeline‐trospium combination in stable patients

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Journals

Actions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Also consider